Dear Doctor Letter (Rote-Hand-Brief) on Maxipime® (cefepime): risk of serious neurologic adverse events in patients with renal impairment
2018.06.18
Active substance: cefepime
Information is circulated on the risk of serious adverse events, including encephalopathy, in patients with renal impairment who received doses that exceeded the recommendations.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN